We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
-2.22%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$69.6M
Cap. Flow
% of AUM
6.48%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$12.7M |
| 2 |
Amazon
AMZN
|
+$9.6M |
| 3 |
Microsoft
MSFT
|
+$7.09M |
| 4 |
Analog Devices
ADI
|
+$4.96M |
| 5 |
Broadcom
AVGO
|
+$4.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Silver Trust
SLV
|
+$7.41M |
| 2 |
ProShares Ultra Gold
UGL
|
+$6.74M |
| 3 |
Arista Networks
ANET
|
+$6.7M |
| 4 |
Gilead Sciences
GILD
|
+$4.85M |
| 5 |
TSMC
TSM
|
+$4.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Design Therapeutics
DSGN
$917M
| $43.8K | ﹤0.01% |
11,357
-649
| -5% | -$3.1K |
|
|
ITOS
427
DELISTED
iTeos Therapeutics
ITOS
| $43.7K | ﹤0.01% |
7,328
-419
| -5% | -$3.08K |
|
428
Annexon
ANNX
$873M
| $41.3K | ﹤0.01% |
21,381
-1,221
| -5% | -$4.06K |
|
429
Corvus Pharmaceuticals
CRVS
$1.27B
| $41K | ﹤0.01% |
12,889
-736
| -5% | -$3.47K |
|
430
Foghorn Therapeutics
FHTX
$394M
| $40.7K | ﹤0.01% |
11,155
-633
| -5% | -$2.89K |
|
431
Inhibrx
INBX
$1.44B
| $40.6K | ﹤0.01% |
2,904
-165
| -5% | -$2.24K |
|
|
YMAB
432
DELISTED
Y-mAbs Therapeutics
YMAB
| $39.8K | ﹤0.01% |
8,984
-513
| -5% | -$2.98K |
|
433
Tevogen Inc. Common Stock
TVGN
$27.3M
| $37.9K | ﹤0.01% |
702
-40
| -5% | -$2.63K |
|
|
CRGX
434
DELISTED
CARGO Therapeutics
CRGX
| $37.6K | ﹤0.01% |
9,232
-528
| -5% | -$3.54K |
|
435
AC Immune
ACIU
$267M
| $37.1K | ﹤0.01% |
19,837
-1,133
| -5% | -$2.85K |
|
436
Voyager Therapeutics
VYGR
$197M
| $37K | ﹤0.01% |
10,957
-626
| -5% | -$2.92K |
|
437
Listed Funds Trust Roundhill Magnificent Seven ETF
MAGS
$4.15B
| $36.7K | ﹤0.01% |
800
-2,401
| -75% | -$125K |
|
|
AMRN
438
Amarin Corp
AMRN
$297M
| $36K | ﹤0.01% |
4,016
-227
| -5% | -$2.4K |
|
|
CMPS
439
Compass Pathways
CMPS
$1.97B
| $35.6K | ﹤0.01% |
12,455
+1,673
| +16% | +$6.42K |
|
440
Neurogene
NGNE
$738M
| $34.9K | ﹤0.01% |
2,980
-170
| -5% | -$2.95K |
|
441
Lexicon Pharmaceuticals
LXRX
$1.05B
| $33.4K | ﹤0.01% |
72,509
-4,141
| -5% | -$2.61K |
|
442
Neumora Therapeutics
NMRA
$317M
| $32.4K | ﹤0.01% |
32,406
-1,851
| -5% | -$3.17K |
|
443
Lyell Immunopharma
LYEL
$347M
| $31.5K | ﹤0.01% |
2,930
-30
| -1% | -$368 |
|
|
THRD
444
DELISTED
Third Harmonic Bio
THRD
| $31.4K | ﹤0.01% |
9,038
-516
| -5% | -$2.5K |
|
445
Wolfspeed
WOLF
$1.65B
| $30.6K | ﹤0.01% |
10,000
| – | – |
|
446
4D Molecular Therapeutics
FDMT
$621M
| $30K | ﹤0.01% |
9,287
-515
| -5% | -$2.43K |
|
447
Tango Therapeutics
TNGX
$4.31B
| $29.7K | ﹤0.01% |
21,685
-1,092
| -5% | -$2.68K |
|
448
Larimar Therapeutics
LRMR
$454M
| $27.5K | ﹤0.01% |
12,799
-730
| -5% | -$2.31K |
|
|
SLN
449
Silence Therapeutics
SLN
$641M
| $26.6K | ﹤0.01% |
9,432
-531
| -5% | -$2.59K |
|
|
SCPH
450
DELISTED
scPharmaceuticals
SCPH
| $26.4K | ﹤0.01% |
10,037
-573
| -5% | -$1.87K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q1 2025 Portfolio in Review
As of Q1 2025, China Universal Asset Management Company held 509 positions worth $1.07B, up 0.55% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
China Universal Asset Management Company deployed $69.6M of net new capital in Q1 2025, opening 13 new positions and adding to 172 existing holdings. Its largest new stake was VNET Group: 300,000 shares worth $2.46M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, down from 38% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was iShares Silver Trust, an estimated $7.41M trimmed.
- China Universal Asset Management Company's largest Q1 2025 buy was VNET Group: 300,000 shares worth $2.46M.
- China Universal Asset Management Company added most to Apple in Q1 2025, an estimated $12.7M increase.
- China Universal Asset Management Company's biggest Q1 2025 reduction was iShares Silver Trust, cutting an estimated $7.41M.
- China Universal Asset Management Company fully exited Arista Networks in Q1 2025, selling an estimated $6.7M.
- China Universal Asset Management Company's ten largest holdings make up 36% of its $1.07B portfolio in Q1 2025.
- China Universal Asset Management Company opened 13 new positions and closed 23 in Q1 2025.
- China Universal Asset Management Company's portfolio value rose 0.55% quarter-over-quarter to $1.07B.
Based on China Universal Asset Management Company's 13F filing for Q1 2025, filed 30 Apr 2025.